Please select the option that best describes you:

Is it sufficient to maintain patients with atrial fibrillation and established PAD on a DOAC or VKA alone, or is there an additional benefit to adding an antiplatelet agent for CVD benefit?  

If so, would you prefer a P2Y12i over low-dose aspirin? 



Answer from: at Academic Institution
Comments
at Corewell Health Medical Center
Are most providers stopping antiplatelet therapy i...
at Yale University School of Medicine
I would generally continue anti-platelet Rx for 12...
Sign in or Register to read more